GV1001

· GemVax & Kael

Drug timelines are a Plus or Pro feature.

12 regulatory and trial events tracked for GV1001, covering 2008-05-19 to 2026-02-23. Get the full timeline:

Most recent: Clinical Trial Update: GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD) [Phase 3]